{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T13:23:25Z","timestamp":1792934605429,"version":"4.5.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Anaplastic thyroid carcinoma (ATC) is one of the most aggressive and lethal thyroid malignancies, with limited effective treatment options. We aimed to identify previously unreported gene alterations and evaluate the potential for clinically actionable targeted therapies in ATC using the largest single next-generation sequencing (NGS) cohort to date.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective genomic analysis included deidentified NGS data from 713 patients with ATC obtained from the FoundationCORE database. Pathogenic gene alterations were analyzed for frequency. A comprehensive review of the literature and genomic databases was performed to identify alterations not previously reported in ATC and to assess associated targeted therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Targeted sequencing of 713 ATC tumor specimens identified 250 genes with pathogenic or likely pathogenic alterations, including 108 not previously reported in ATC. Among these novel genes, 24 were altered in 5 or more cases, with MTAP (methylthioadenosine phosphorylase) showing the highest frequency (15.26%). MTAP was also co-deleted with CDKN2A\/B at significantly higher rates than previously reported. Notably, 99.58% of cases harbored at least 1 gene alteration associated with a potentially actionable therapy. Among the 250 altered genes, 150 (60.0%) had at least 1 available corresponding targeted therapy, and 75.0% of drug categories demonstrated multiple-gene targeting capabilities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This largest single-cohort NGS data analysis identified 108 previously unreported genomic alterations in ATC, significantly expanding the understanding of the genomic landscape of this aggressive cancer. Moreover, these findings highlight a broad range of potentially actionable alterations and underscore the importance of identifying driver mutations and combination therapeutic strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajcp\/aqag092","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T11:22:48Z","timestamp":1783941768000},"source":"Crossref","is-referenced-by-count":1,"title":["Single-cohort next-generation sequencing analysis of 713 anaplastic thyroid carcinomas: unreported gene alterations and actionable targets"],"prefix":"10.1093","volume":"166","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6445-7497","authenticated-orcid":false,"given":"Xiaoming","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Pathology and Anatomical Sciences, University of Missouri School of Medicine , Columbia, MO,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naiwei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, Biostatistics and Medical Epidemiology, University of Missouri School of Medicine , Columbia, MO,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Claxton","sequence":"additional","affiliation":[{"name":"Department of Pathology and Anatomical Sciences, University of Missouri School of Medicine , Columbia, MO,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6016-5534","authenticated-orcid":false,"given":"Mikhail","family":"Kovalenko","sequence":"additional","affiliation":[{"name":"Department of Pathology and Anatomical Sciences, University of Missouri School of Medicine , Columbia, MO,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6075-6246","authenticated-orcid":false,"given":"Dean C","family":"Pavlick","sequence":"additional","affiliation":[{"name":"Foundation Medicine , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew C","family":"Hiemenz","sequence":"additional","affiliation":[{"name":"Foundation Medicine , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M","family":"Dooley","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, University of Missouri School of Medicine , Columbia, MO,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7173-9414","authenticated-orcid":false,"given":"Richard D","family":"Hammer","sequence":"additional","affiliation":[{"name":"Department of Pathology and Anatomical Sciences, University of Missouri School of Medicine , Columbia, MO,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,8]]},"reference":[{"key":"2026080808305032200_aqag092-B1","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/nrendo.2017.76","article-title":"Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies","volume":"13","author":"Molinaro","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"2026080808305032200_aqag092-B2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"2026080808305032200_aqag092-B3","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.wjorl.2018.05.006","article-title":"Is the incidence of anaplastic thyroid cancer increasing: a population based epidemiology study","volume":"5","author":"Janz","year":"2019","journal-title":"World J Otorhinolaryngol Head Neck Surg"},{"key":"2026080808305032200_aqag092-B4","first-page":"5888","article-title":"The incidence and survival analysis for anaplastic thyroid cancer: a SEER database analysis","volume":"11","author":"Lin","year":"2019","journal-title":"Am J Transl Res"},{"key":"2026080808305032200_aqag092-B5","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1089\/thy.2020.0086","article-title":"Dissecting anaplastic thyroid carcinoma: a comprehensive clinical, histologic, immunophenotypic, and molecular study of 360 cases","volume":"30","author":"Xu","year":"2020","journal-title":"Thyroid"},{"key":"2026080808305032200_aqag092-B6","doi-asserted-by":"publisher","first-page":"4506","DOI":"10.1210\/jc.2017-01180","article-title":"Survival in response to multimodal therapy in anaplastic thyroid cancer","volume":"102","author":"Prasongsook","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"2026080808305032200_aqag092-B7","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1089\/thy.2012.0302","article-title":"American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer","volume":"22","author":"Smallridge","year":"2012","journal-title":"Thyroid"},{"key":"2026080808305032200_aqag092-B8","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/S0140-6736(13)60109-9","article-title":"Progress in molecular-based management of differentiated thyroid cancer","volume":"381","author":"Xing","year":"2013","journal-title":"Lancet"},{"key":"2026080808305032200_aqag092-B9","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1158\/1078-0432.CCR-18-0373","article-title":"Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers","volume":"24","author":"Pozdeyev","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2026080808305032200_aqag092-B10","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1038\/s41467-019-10680-5","article-title":"Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer","volume":"10","author":"Yoo","year":"2019","journal-title":"Nat Commun"},{"key":"2026080808305032200_aqag092-B11","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1002\/hed.25634","article-title":"Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling","volume":"41","author":"Khan","year":"2019","journal-title":"Head Neck"},{"key":"2026080808305032200_aqag092-B12","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1093\/hmg\/ddu749","article-title":"Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing","volume":"24","author":"Kunstman","year":"2015","journal-title":"Hum Mol Genet"},{"key":"2026080808305032200_aqag092-B13","doi-asserted-by":"publisher","first-page":"42613","DOI":"10.18632\/oncotarget.17300","article-title":"NGS based identification of mutational hotspots for targeted therapy in anaplastic thyroid carcinoma","volume":"8","author":"Tiedje","year":"2017","journal-title":"Oncotarget"},{"key":"2026080808305032200_aqag092-B14","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1089\/thy.2016.0254","article-title":"Molecular pathology of anaplastic thyroid carcinomas: a retrospective study of 144 cases","volume":"27","author":"Bonhomme","year":"2017","journal-title":"Thyroid"},{"key":"2026080808305032200_aqag092-B15","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.annonc.2021.12.014","article-title":"Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study","volume":"33","author":"Subbiah","year":"2022","journal-title":"Ann Oncol"},{"key":"2026080808305032200_aqag092-B16","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1158\/1078-0432.CCR-21-3597","article-title":"Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors","volume":"28","author":"Demetri","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026080808305032200_aqag092-B17","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of selpercatinib in RET-altered thyroid cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N Engl J Med"},{"key":"2026080808305032200_aqag092-B18","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S2213-8587(21)00120-0","article-title":"Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1\/2 study","volume":"9","author":"Subbiah","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026080808305032200_aqag092-B19","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","article-title":"Memorial Sloan Kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology","volume":"17","author":"Cheng","year":"2015","journal-title":"J Mol Diagn"},{"key":"2026080808305032200_aqag092-B20","doi-asserted-by":"publisher","first-page":"e0264138","DOI":"10.1371\/journal.pone.0264138","article-title":"Clinical and analytical validation of FoundationOne\u00aeCDx, a comprehensive genomic profiling assay for solid tumors","volume":"17","author":"Milbury","year":"2022","journal-title":"PLoS One"},{"key":"2026080808305032200_aqag092-B21","author":"Hammer","year":"2024"},{"key":"2026080808305032200_aqag092-B22","author":"Hammer","year":"2024"},{"key":"2026080808305032200_aqag092-B23","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat Biotechnol"},{"key":"2026080808305032200_aqag092-B24","author":"US Food and Drug Administration","year":"2025"},{"key":"2026080808305032200_aqag092-B25","doi-asserted-by":"publisher","first-page":"476","author":"Humble","DOI":"10.1038\/s41379-022-01035-5"},{"key":"2026080808305032200_aqag092-B26","doi-asserted-by":"publisher","author":"Jansen","DOI":"10.1093\/ajcp\/aqae129.151"},{"key":"2026080808305032200_aqag092-B27","doi-asserted-by":"publisher","first-page":"113826","DOI":"10.1016\/j.celrep.2024.113826","article-title":"The genomic and evolutionary landscapes of anaplastic thyroid carcinoma","volume":"43","author":"Zeng","year":"2024","journal-title":"Cell Rep"},{"key":"2026080808305032200_aqag092-B28","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.dnarep.2006.11.001","article-title":"MUTYH-associated polyposis\u2014from defect in base excision repair to clinical genetic testing","volume":"6","author":"Cheadle","year":"2007","journal-title":"DNA Repair (Amst)"},{"key":"2026080808305032200_aqag092-B29","doi-asserted-by":"publisher","first-page":"6373","DOI":"10.1210\/jc.2005-0987","article-title":"BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer","volume":"90","author":"Xing","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2026080808305032200_aqag092-B30","doi-asserted-by":"publisher","author":"Kovalenko","DOI":"10.1093\/ajcp\/aqae129.275"},{"key":"2026080808305032200_aqag092-B31","doi-asserted-by":"publisher","author":"Zhang","DOI":"10.1093\/ajcp\/aqae129.152"},{"key":"2026080808305032200_aqag092-B32","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1158\/1535-7163.MCT-17-0871","article-title":"Molecular profile of advanced thyroid carcinomas by next-generation sequencing: characterizing tumors beyond diagnosis for targeted therapy","volume":"17","author":"Chen","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"2026080808305032200_aqag092-B33","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s12022-016-9445-4","article-title":"Genomic landscape of poorly differentiated and anaplastic thyroid carcinoma","volume":"27","author":"Xu","year":"2016","journal-title":"Endocr Pathol"},{"key":"2026080808305032200_aqag092-B34","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1089\/thy.2015.0506","article-title":"Genomic alterations of anaplastic thyroid carcinoma detected by targeted massive parallel sequencing in a BRAF(V600E) mutation-prevalent area","volume":"26","author":"Jeon","year":"2016","journal-title":"Thyroid"},{"key":"2026080808305032200_aqag092-B35","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1530\/EC-18-0386","article-title":"Not the same thing: metastatic PTCs have a different background than ATCs","volume":"7","author":"de Biase","year":"2018","journal-title":"Endocr Connect"},{"key":"2026080808305032200_aqag092-B36","author":"Hammer","year":"2023"},{"key":"2026080808305032200_aqag092-B37","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41379-019-0310-0","article-title":"MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma","volume":"33","author":"Chapel","year":"2020","journal-title":"Mod Pathol"},{"key":"2026080808305032200_aqag092-B38","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/jnen\/nlad109","article-title":"Reliability assessment of methylthioadenosine phosphorylase immunohistochemistry as a surrogate biomarker for CDKN2A homozygous deletion in adult-type IDH-mutant diffuse gliomas","volume":"83","author":"Gundogdu","year":"2024","journal-title":"J Neuropathol Exp Neurol"},{"key":"2026080808305032200_aqag092-B39","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/s41379-020-00701-w","article-title":"Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma","volume":"34","author":"Satomi","year":"2021","journal-title":"Mod Pathol"},{"key":"2026080808305032200_aqag092-B40","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/his.15324","article-title":"MTAP protein status is highly concordant with CDKN2A fluorescent in situ hybridization and allows stratification of the luminal subtype in muscle-invasive bladder cancer","volume":"86","author":"Olkhov-Mitsel","year":"2025","journal-title":"Histopathology"},{"key":"2026080808305032200_aqag092-B41","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1093\/carcin\/bgl093","article-title":"Increased frequency of disease-causing MYH mutations in colon cancer families","volume":"27","author":"Peterlongo","year":"2006","journal-title":"Carcinogenesis"},{"key":"2026080808305032200_aqag092-B42","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(03)13805-6","article-title":"Autosomal recessive colorectal adenomatous polyposis due to inherited mutations of","volume":"362","author":"Sampson","year":"2003","journal-title":"Lancet"},{"key":"2026080808305032200_aqag092-B43","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1053\/j.gastro.2014.01.022","article-title":"Risk of colorectal cancer for carriers of mutations in MUTYH, with and without a family history of cancer","volume":"146","author":"Win","year":"2014","journal-title":"Gastroenterology"},{"key":"2026080808305032200_aqag092-B44","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s10689-010-9366-1","article-title":"Papillary thyroid cancer in a patient with MUTYH-associated polyposis (MAP)","volume":"9","author":"Pervaiz","year":"2010","journal-title":"Fam Cancer"},{"key":"2026080808305032200_aqag092-B45","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","article-title":"Integrated genomic characterization of papillary thyroid carcinoma","volume":"159","author":"Agrawal","year":"2014","journal-title":"Cell"},{"key":"2026080808305032200_aqag092-B46","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600\u2013mutant anaplastic thyroid cancer","volume":"36","author":"Subbiah","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026080808305032200_aqag092-B47","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaoncol.2023.1379","article-title":"Diagnosis and management of tropomyosin receptor kinase fusion-positive thyroid carcinomas: a review","volume":"9","author":"Haddad","year":"2023","journal-title":"JAMA Oncol"},{"key":"2026080808305032200_aqag092-B48","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1200\/JCO.2022.40.16_suppl.3099","article-title":"Updated analysis of the efficacy and safety of entrectinib in patients (pts) with locally advanced\/metastatic NTRK fusion-positive (NTRK -fp) solid tumors","volume":"40","author":"Krzakowski","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026080808305032200_aqag092-B49","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1177\/10600280241241531","article-title":"Capivasertib: a novel AKT inhibitor approved for hormone-receptor-positive, HER-2-negative metastatic breast cancer","volume":"58","author":"Luboff","year":"2024","journal-title":"Ann Pharmacother"},{"key":"2026080808305032200_aqag092-B50","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s40265-024-01998-6","article-title":"Capivasertib: first approval","volume":"84","author":"Shirley","year":"2024","journal-title":"Drugs"}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/166\/2\/aqag092\/70552355\/aqag092.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/166\/2\/aqag092\/70552355\/aqag092.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T12:30:57Z","timestamp":1786192257000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/doi\/10.1093\/ajcp\/aqag092\/8756802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,8,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqag092","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"value":"0002-9173","type":"print"},{"value":"1943-7722","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,8]]},"article-number":"aqag092"}}